The benefits of taking ADHD medications and the risks of not taking them. 

---

1. ADHD Without Treatment Can Erode Neuroplasticity

• Chronic underactivation of the prefrontal cortex (PFC) in ADHD means the brain’s executive networks are less engaged in sustained, goal-directed tasks.
• When neural pathways are underused, synaptic pruning and disuse can lead to less robust connections in the PFC, anterior cingulate, and basal ganglia circuits.
• Over time, this can reduce the brain’s capacity to adapt and learn — i.e., neuroplasticity declines.

2. Stimulants Normalize Dopamine & Norepinephrine Transmission

• Adderall increases dopamine and norepinephrine availability in the PFC and striatum by blocking reuptake and promoting release.
• These neurotransmitters are crucial for synaptic plasticity, especially in learning-related circuits.
• By restoring more typical levels of catecholamines, medication re-engages the PFC, improving attention, working memory, and self-regulation.
• Healthy, repeated activation of these circuits promotes long-term strengthening (Hebbian learning: “neurons that fire together, wire together”).
• 3. Protects Against “Downstream” Damage from Life ImpairmentsBarkley often emphasizes that ADHD isn’t just about symptoms — it’s about the cascading impairments over time:
• Untreated ADHD → more accidents, substance abuse, academic failure, job loss, financial stress, relationship instability.
• These chronic stressors increase allostatic load (wear and tear on the brain and body), which can harm neural health and plasticity.
• Medication reduces symptom severity, which reduces life chaos, which in turn protects the brain from stress-related neurodegeneration.

---

4. Reduces Risk for Comorbidities That Harm the Brain

• Untreated ADHD increases the risk of depression, anxiety, substance use disorders, and even dementia.
• Chronic stress and comorbid mental illness can lead to structural brain changes (e.g., hippocampal shrinkage in major depression).
• Medication lowers the risk or severity of these comorbidities, thereby preserving brain structure and function.

5. Encourages Adaptive Neural Remodeling in Adulthood

• Stimulants don’t just help children — they help adults maintain cognitive engagement in work, relationships, and learning.
• By keeping the brain consistently challenged and engaged, medication creates conditions for lifelong neuroplasticity (something Barkley stresses is critical in preventing premature cognitive decline).

6. Early Intervention Is Especially Protective

• Barkley often notes that children treated earlier tend to have better long-term outcomes:
  • Fewer school dropouts
  • Lower substance abuse risk
  • Better occupational and social functioning
• The reasoning: Early treatment keeps executive circuits engaged during critical developmental windows, preventing maladaptive rewiring.

In short:
Stimulant medication is neuroprotective in ADHD because it:

1. Keeps executive circuits active and efficient.
2. Maintains healthy dopamine/norepinephrine signaling, essential for learning and synaptic growth.
3. Reduces life chaos and chronic stress, preventing damage from allostatic overload.
4. Prevents secondary conditions that degrade brain health.
5. Promotes adaptive rewiring well into adulthood.

References
Arnsten, A. F. T. (2009). Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs, 23(1), 33–41. https://doi.org/10.2165/0023210-200923010-00004

Barkley, R. A. (2015). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (4th ed.). New York, NY: Guilford Press.

Barkley, R. A. (2012). Executive functioning and self-regulation viewed as an extended phenotype: Implications of the theory for ADHD and its treatment. In R. A. Barkley (Ed.), Executive functions: What they are, how they work, and why they evolved (pp. 287–313). New York, NY: Guilford Press.

Biederman, J., Petty, C. R., Clarke, A., Lomedico, A., & Faraone, S. V. (2011). Predictors of persistent ADHD: An 11-year follow-up study. Journal of Psychiatric Research, 45(2), 150–155. https://doi.org/10.1016/j.jpsychires.2010.06.009

Faraone, S. V., Biederman, J., & Mick, E. (2006). The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychological Medicine, 36(2), 159–165. https://doi.org/10.1017/S003329170500471X

Faraone, S. V., & Buitelaar, J. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child & Adolescent Psychiatry, 19(4), 353–364. https://doi.org/10.1007/s00787-009-0054-3

Rubia, K. (2018). Cognitive neuroscience of attention deficit hyperactivity disorder (ADHD) and its clinical translation. Frontiers in Human Neuroscience, 12, 100. https://doi.org/10.3389/fnhum.2018.00100

Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014). Emotion dysregulation in attention deficit hyperactivity disorder. American Journal of Psychiatry, 171(3), 276–293. https://doi.org/10.1176/appi.ajp.2013.13070966

​Volkow, N. D., Wang, G. J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., … Swanson, J. M. (2009). Evaluating dopamine reward pathway in ADHD: Clinical implications. JAMA, 302(10), 1084–1091. https://doi.org/10.1001/jama.2009.1308